Utilization of the Baylis-Hillman and related reactions in antiparasitic drug discovery by Mabizela, Nontobeko
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
Published by the University of Cape Town (UCT) in terms 










UTILIZATION OF THE BA YLIS·HILLMAN AND RELATED 
REACTIONS IN ANTIPARASITIC DRUG DISCOVERY 
By 
NONTOBEKO MABIZELA 
A thesis presented for the degree of 
MASTERS OF SCIENCE 
In the Department of Chemistry 
UNIVERSITY OF CAPE TOWN 
Supervisor: 














CHAPTER 1- INTRODUCTION TO DISEASES 1 
1 . 1 Malaria 1 
1.1.1 Introduction 1 
1.1.2 Life cycle 2 
1.1.3 fIistory of malaria chemotherapy 4 
1.2 American Trypanosomiasis 8 
1.2.1 Introduction 8 
1.2.2 Chemotherapy 8 
1.3 Parasitic cysteine proteases 9 
CHAPTER 2- THE BAYLIS-HILLMAN REACTION 12 
2. 1 Introduction 12 
2.2 Rationale behind utilization ofB-H in antiparasitic drug discovery 17 
CHAPTER 3- RESULTS AND DISCUSSION 23 










3.1.1 Synthesis of target compounds 23 
3.1.1.1 Synthesis of class 1 compounds 23 
3.1.1.2 Synthesis of class 2 compounds 24 
3.1.1.3 Synthesis of class 4 compounds 27 
3.1.1.4 Synthesis of class 5 compounds 30 
3.1.3 Support bound reagents as potential catalysts for the B-H reaction 32 
3.1.2.1 Synthesis of class 3 compounds 39 
CHAPTER 4- BIOLOGICAL RESULTS AND DISCUSSION 45 
4.1 Activity of selected compounds against cruzain and T cruzi 45 
4.1. 1 T Cruzi in culture 48 





5.2 General method for the preparation of targets 18,21,23,24 and 25 
5.3 Procedure for the preparation of target compounds 22, 26 and 27 
5.3.1 Procedures for the starting materials 
5.3.2 General procedure for preparation of 22 and 26 
5.4 General procedure Jor the preparation of ester acrylates 56 




















5.6 General procedure fbr the preparation of 48-57 67 
5.7 Procedure for the preparation of com:pound.%~ and S5 70 
5.8 General procedureJur ByH reactions 71 













I declare that "Utilization of the Baylis-Hillman and related reactions in antiparasitic drug 
discovery" is my own work and that all sources I have used or quoted have been 













Firstly, I would like to thank the Lord Almighty who has been with me throughout and 
made me realize that I can do all things through Christ who strengthens me. Secondly, I 
would like to thank my supervisor, Assoc. Prof. Kelly Chibale, who was so patient and 
always willing to help. I have learnt a lot since I started working with him and will 
forever be grateful and treasure the experience I gained. With loads of love I would also 
like to thank my parents who did not only give me love but support through the years of 
my studies. To Nontokozo and Lwazi, thank you. To my brother Sizwe, Phethiwe and 
their kids, I'm eternally grateful for your support and love, none of this would have been 
possible if it wasn't for your support and helping me to keep my eye on the goal. In no 
specific order of importance, I would like to express my gratitude to Alex Chipeleme, for 
all his help and encouragement, and to the rest of the Medicinal Chemistry lab members. 
Thank you also to A. N chinda for all his inputs and assistance. 
My further thanks to collaborators at the University of California San Francisco (USA) in 
whose laboratories the biological assays were performed: Prof J. H McKerrow for 
cruzain and T. cruzi and ProfP. J Rosenthal for Falcipain-2 and P. falciparum. 
Finally I would like to thank Pete Roberts and Noel Hendricks for NMR experiments, 
Piero Benincasa for microanalysis, Mr. 1. Minaar and Dr Boshoff for mass spectra. My 
gratitude is also extended to the National Research Foundation (NRF) and University of 












Baylis-Hillman adducts and compounds containing quinoline moieties have been 
previously utilized extensively in the search for antiparasitic agents. Work in this 
dissertation describes a series of compounds based on the Baylis-Hillman and the related 
three-component aza Baylis-Hillman reactions synthesised for biological evaluation as 
potential inhibitors of two parasitic cysteine proteases (cruzain and Falcipain-2) and as 
antiparasitic agents. The utilization of polymer-supported bases in the Baylis-Hillman 
reaction is described. The use of ultrasound in combination with Lewis acids is also 
described in an attempt to improve the reaction rate. 
Of the different compounds synthesized and tested, 2-[quinolin-4-yl-(toluene-4-
sulfonylamino)-methyl]-acrylic acid tert-butyl ester showed the most promise as a 
potential antitrypanosomal agent. On the other hand the corresponding Baylis-Hillman 
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INTRODUCTION TO DISEASES 
Malaria is a senous, sometimes fatal disease caused by a parasite. It is one of the 10 
most prevalent and deadly diseases in the world. The World Health Organization 
estimates that 300 to 500 million clinical cases occur every year with over 1.2 to 2.7 
million deaths [1] 90% of these occur in sub-Saharan Africa, 800 to 1000 cases of 
malaria are reported in Australia each year and about 1,200 cases of malaria are 
diagnosed in the United States each year. It is a parasitic disease spread by the bite of 
anopheles mosquito, which is active between dusk and dawn. There are four kinds of 
malaria parasites that can infect humans: Plasmodium falciparum, P. vi vax. P. ovale 
and P. malariae. P. falciparum is the most serious and prevalent. The principal 
symptoms of P. !atcipurum malaria include fever and flu-like illness, shaking chills, 
headache, muscle aches, tiredness and sweats but it can also present as a respiratory or 
gastrointestinal illness. Nausea, vomiting, and diarrhea may also occur. Malaria may 
cause anaemia and jaundice (yellow coloring of the skin and eyes) because of the loss 
of red blood cells. Infection with one type of malarial. P. falciparum. if not promptly 
treated, may cause kidney failure, seizures, mental confusion, coma, and death. For 
most people, symptoms begin 10 days to 4 weeks after infection, although a person 
may feel ill as early as 8 days or up to 1 year later. Two kinds of malaria, P. vivax and 
P. a vale. can relapse; some parasites can rest in the liver for several months up to 4 
years after a person is bitten by an infected mosquito. When these parasites come out' 











In addition the available antimalarial drugs are loosing efficacy because the malaria 
parasite has developed resistance to most existing antimalarials. Chloroquine is an 
exceptionally safe antimalarial and has been used widely for more that 40 years. 
However, its value has been compromised by the emergence of chloroquine resistant 
P. falciparum [21 . Therefore there is an urgent need for the development of alternative 
drugs. 
1.1.2 Life cycle of Plasmodium [2] 
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Figure 1. 
The parasite W1dergoes a development stage in the female anophele species, which 
requires a blood meal to mature her eggs. She bites a hwnan and injects material from 
her salivary glands, which contains primitive malarial parasites called sporozoites, 











settle in the liver ""here they enter the parenchymal cells and multiply; this stage is 
known as pre-erythrocytic schizogony. After about 12 days there may be many 
thousands of young parasites known as merozoites in one liver cell (hepatic 
parenchyma cell), the cell ruptures and the free merozoites enter red blood cells. In 
the case of P. vi vax, and P.ovale the liver cycle continues and requires a course of 
primaquine to eliminate it. Pfalciparum on the other hand does not have a continuing 
liver cycle. 
In the red blood cells the parasites develop into two forms, a sexual and an asexual 
cycle. The sexual cycle produces male and female gametocytes, which circulate in the 
blood and are taken up by a female mosquito when taking a blood meal. The male and 
female gametocytes fuse in the mosquito'S stomach and form oocysts in the wall of 
the stomach. Thest' oocysts develop over a period of days and contain large numbers 
of sporozoites, whlch move to the salivary glands and are ready to be injected into 
man when the mosquito next takes a meal. In the asexual cycle the developing 
parasites form schlzonts in the red blood cells, which contain many merozoites, the 
infected red cells l-upture and release a batch of young parasites, merozoites, which 
invade new red cells [3]. In P. vivax, P.ovale and probably P.malariae, all stages of 
development subsequent to the liver cycle can be observed in the peripheral blood. 
However, in the case of P. falciparum only ring forms and gametocytes are usually 
present in the perioheral blood. Developing forms appear to stick in the blood vessels 
of the large organs such as the brain and restrict the blood flow with serious 
conseq uences. 
In falciparum malaria the parasites multiply very rapidly and may occupy 30% or 











for this is that P. jdciparum invades red cells of all ages whereas P. vivax and P 
ovale prefer younger red cells, while P malariae seeks mature red cells. 
1.1.3 History of malaria chemotherapy 
Malaria chemotherapy began in the I t h century after a patient took a remedy made 
from the cinchona tree bark. Quinine 1 has been used for more than three centuries 
and until the 1930's it was the only effective agent for the treatment of malaria It is 
one of the four main alkaloids found in the bark of the Cinchona tree and is the only 
drug which over a long period of time has remained largely effective for treating the 
disease. It is now cnly used for treating severe falciparum malaria partly because of 
undesirable side effects. In Africa in the 1930's and 40's it was known for people to 
take quinine when they thought they had "a touch of malaria" and the association of 
repeated infections with falciparum malaria and inadequate treatment with quinine, 
resulted in the development in some of acute massive intravascular haemolysis and 

























Pamaquine (2) Quinacrine (3) 
Atovaquone (5) Halofantrine (6) 

















Although Pamaquine 2 was developed as the first 8-aminoquinoline that proved to be 
the first compound capable of preventing relapse in vivax malaria in 1925, quinacrine 
(mepacrine) 3 was the first effective compound to be developed against falciparum 
malaria in 1932. Thf drug became so popular that it wasn't possible to have enough 
supply, therefore the shortfall as well as the side effects led to intensiflcation of 
efforts for developing synthetic quinine analogues as antimalarials. 
Also known as chloroquinadine is proguanil 4 121. This drug falls into the biguanide 
class of the antimalarials and was first synthesized in 1946. The drug is a folate 
antagonist and destroys the malaria parasite by binding to the enzyme dihydrofolate 
reductase in much the same way as pyrimethamine. It is still used as a prophylactic in 
some countries. In 1998 a new drug combination was released in Australia called 
Malarone. This is a combination of proguanil 4 and atovaquone 5. Atovaquone 5 
became available in 1992 and was used with success for the treatment of pneumocytic 
carrmii. When combined with proguanil 4 there is a synergistic effect and the 
combination is at the present time very effective. The drug combination has 
undergone several large clinical trials and has been found to be 95% effective in 
otherwise drug resistant falciparum malaria Halofantrine 6 is another drug, which 
belongs to the class of compounds called phenanthrene-methanols and is not related to 
quinine. It is an effective antimalarial introduced in 1980s, but due to it's short half-
life of 1 to 2 days, is not suitable for use as a prophylactic. Unfortunately resistant 
forms are increasingly being reported and there is some concern about side effects. 
Chloroquine [4] 7 is a very effective 4-amino-quinoline both for treatment and 
prophylaxis. It was first used in the 1940s shortly after the Second World War and 
was effective in curing all forms of malaria; with few side effects when taken in the 












falciparum malaria ere now resistant to chloroquine and more recently chloroquine 
resistant vivax mal"ria has also been reported. In case of generalized psoriasis, 
chloroquine and other chloroquine-like drugs, including primaquine, quinidine and 
proguanil 3 should b~ avoided. 
]f Mefloquine 8 is to be used to combat malaria it is probably best to start the 
treatment 4 weeks h~fore entering a malarious area as it takes this long to build up to 
satisfactory blood levels. It is a readily tolerated antimalarial drug active against both 
the sensitive and the resistant strain of P. falciparum. Because of its relation to 
quinine the two drugs must not be used together. There has been a report of various 
undesirable side effects including acute brain syndrome. Doxycycline is an alternative 
to mefloquine for short-term treatment. 
A Mannich base derivative, amodiaquine 9, introduced into the field in the late 1950s, 
has been shown to be a superior alternative to CQ in the areas of high CQ resistance 
[5] Unfortunately in the mid-l 980s, the use of amodiaquine declined abruptly 
following initial reports of agranulocytosis and hepatitis when the drug was used. 
Artemisinin [6] 10 is derived from a Chinese herbal remedy and covers a group of 
products. The two most widely used are artesunate and arternether. While they are 
widely used in South East Asia they are not licensed in much of the so-called 
"western world". A high rate of treatment faIlures has been reported and it is now 
being combined with mefloquine for the treatment of falciparum malaria [71. 
Primaquine 11 is the only available drug for the treatment and clearing of Plasmodia 
from the liver and lS thus used in the cure for P. vivax and P. ovale. However toxic 










1.2 American Trypanosomiasis 
1.2.1 Introduction 
8 
American Trypanosomiasis otherwise known, as Chagas' disease is a parasitic disease 
caused by kinetoplastid protozoan parasite Trypanosoma cruzi. It is responsible for 
the deaths of millicns of people in Latin America [8] It represents a serious problem 
for public health, as there are currently no satisfactory methods of immune 
prophylaxis or chemotherapy. The life cycle starts when an infected insect vector 
takes a blood meal and releases trypomastigotes in its faeces near the site of the bite 
wound. Trypomasrigotes enter the host through the wound or through intact mucosal 
membranes, such as the conjunctiva. Inside the host, the trypomastigotes invade cells 
and differentiate into amastigotes. Amastigotes are released infecting new cells and 
some transforming into trypomastigotes and remain in the blood stream. The vector 
becomes infected when it ingests amastigotes or trypomastigote in a blood meal. The 
parasite reproduces asexually in the vectors gut becoming infective metacyclic 
trypomastigote in the midgut. 
1.2.2 Chemotherapy 
There is a continuous interest in the development of new specific chemotherapeutic 
approaches for American trypanosomiasis. The main drug in use is Nifurtimox [9] 12 
but it has undesirable side effects and is inefficient in treating the chronic state of the 
disease [8l. It only affects total parasite clearance in 50% of the patients. Among the 
most promising new approaches are sterol biosynthesis inhibitors (SBI) exemplified 
by Ruvucunazole 13. Ruvuconazole 13 is a very potent and specific anti- T. cruzi 
agent in vitro but its in vivo activity is limited, probably due to its unfavourable 











potential utility of ntvuconazole in the treatment of T cruzi infections, 
Nifurtimox (12) Ruvuconazole (13) 
Figure 3. Chemical structures of drugs used in the treatment of Chagas disease, 
1.3 Parasitic cysteine proteases 
Cysteine proteases (CPs) exemplify common enzyme targets present in different 
parasites, They play numerous indispensable roles in the biology of parasitic 
orgarnsms, Interest in CPs as targets for the development of antiparasitic 
chemotherapy derives from the recognition that they playa key role at various stages 
in the life cycle or pathogenicity of many parasites, Parasitic cysteine proteases 
inhibitors are generally compounds to which the thiol of the cysteine residue in the 
enzyme active site adds, The proposed general catalytic mechanism for the CPs, in 
which an active site thiol is utilised for hydrolysis, is shown in Figure 4, Histidine 
polarizes the enzyme cysteine thiol group of (Enz-Cys) allowing deprotonation even 
under nearly neutral to weakly acidic pH conditions, The resulting highly nucleophilic 
thiolatelimidazoliwn ion pair allows the thiolate anion to attack the carbonyl carbon 
of the scissile amide bond resulting in a tetrahedral intermediate, This is followed by 











intermediate is the~1 formed via hydrolysis of the acyl-enzyme. The enzyme is 
regenerated following collapse of the second tetrahedral intermediate and product 
release. 
As mentioned earlier parasites use cysteine proteases for important biological tasks. 
Among such parasites are T cruzi, P. faiciparum and Leishmanial major [IH3] 
Cruzain [14] is the major cysteine protease of T. cruzi, which is essential for 
replication, and differentiation of the intracellular parasite. Cruzain thus represents an 
attractive chemotherapeutic target for treatment of Chagas' disease. Similarly 
Falcipain-2, a cysteine protease isolated from P. falciparum, has been shown to be 
involved in hemoglobin degradation, which appears to be necessary for the growth of 
the erythrocytic malaria parasite. The major cathepsin L and B-like protease of 
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THE BAYLIS-HILLl\IlAN REACTION 
2.1 Introduction 
The Baylis-Hillman (B-H) (15) reaction involves coupling an activated alkene with 
electrophiles (usually aldehydes) using a base (usually an amine) as a catalyst, Scheme l. 
The B-H reaction is among the most economical and useful carbon-carbon bond forming 
reactions in organic synthesis. There are a number of different bases and catalyst systems 
used in this reaction. Amongst them are DMAP, 3-hydroxyquinidine, cinchonidine, 
PPh3, quinidine and quinidine derivatives in aqueous THF [16]-[17] 
But the most frequently used catalysts are non-nucleophilic sterically-hindered tertiary 
amines like DBU 14, or DABCO 15 (18]. Recently it has been shown that DBU is superior 
to DABCO by a factor of 50 as it produces a 50-fold increase in the rate of the reaction 
[18] The key to the actIvity ofDBU is thought to be the fact that the enolate is stabilized 





There are a number of problems commonly associated with this reaction, most notably 
it's slow reaction rate, with some B-H reactions taking days or weeks to go to 











reaction time, low-temperature techniques [19] and the addition of Lewis acids [20]-[21] such 
as lanthanide triflates ::>r LiCI04 and the use of ultrasound [20]-[21] These efforts even 
when successful in improving the rate of the Baylis-Hillman reaction are only applicable 
to a limited number of substrates. 
+ 
X =NR", 0 





The general accepted mechanism for the Baylis-Hillman reaction for an acrylate ester is 















Figure 5. Mechanism for the Baylis Hillman reaction for an acrylate ester. 
14 
From the above mechanism, it is postulated that the nucleophilic 1,4-conjugate addition 
of the catalyst to the activated alkene affords an enolate, which then reacts with the 
electrophilic aldehyde to give the zwitterion. Elimination of the catalyst followed by 
protonation affords the B-H product with the catalyst being regenerated. Alternatively, an 
internal proton transfer may occur to give the resonance-stabilized zwitterions, which 











A B-H reaction in which the product is a substituted sulfonamide derivative is an 

















The mechanism for the aza-Baylis-Hillman reaction catalyzed by triphenylphosphine is 
roughly illustrated in Figure 6. 
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2.2 Rationale behind utilization of B-Hand aza B-H in antiparasitic drug discovery. 
We reasoned that the B-H has potential application in drug discovery efforts against 
parasitic diseases for the following reasons: 
(i) There is literature precedent for B-H adducts and their derivatives as 
antimalarial agents [26] These are exemplified by 16 and 17. 
OH 
~x 
l . .J II 
N 
16 17 
(ii) There is structural similarity between B-H adducts and antimalarial 4-
















(iii) The presence of the u, ~-unsaturated moiety in B-H adducts could render these 
potential inhibitors of cysteine proteases including cruzain and falcipain-2 . B-
H adducts could be envisaged to undergo 1,4-conjugate addition with the thiol 














(iv) The aza-B-H is a 3-component reaction, which could provide a powerful 
strategy for delineating structure-activity relationships. Furthermore, the 
antimalarial activity of aza-B-H adducts have not been reported todate. 
(v) Both the B-H and aza-B-H adducts are highly functionalised compounds 












These considerations led to the design of compounds 18-53 for exploratory studies 
against the parasitic cysteine proteases, falcipain-2 and cruzain as well as the parasites 
themselves. 
Incorporation of a quinoline moiety (Class 1 and 2) was expected to increase 
accumulation of the compound in the acidic food vacuole of the malaria parasite. 
HO OR 
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18: R= t-Bu 19: R= H, 
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Class 3 compounds were designed in order to explore the effect of different substituents 
on the biological activity. 
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Class 4 compounds are aza-B-H adducts in which the alkene activating group is varied 
between the nitrile and ester. 
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X= t-Butyloxycarbonyl X=CN 
42: Ar= 
44: Ar = 45: Ar= 
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Class 5 compounds were designed in order explore the effect of incorporating a quinoline 
moiety as part of the acrylate substrate with a view to maximizing antimalarial activity. 
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RESULTS AND DISCUSSION 
3.1 Chemistry 
3.1.1 Synthesis of target compounds 
3.1.1.1 Synthesis of class 1 compounds 
These compounds were synthesised by stirring a mixture of 4-quinoline-carbaldehyde 
and the acrylate in DBU at room temperature for 23hrs. The product mixtures were 
purified by column chromatography affording B-H adducts in moderate to high 
yields, Table l. Compounds, which were synthesized in this way, were identified by 
the characteristic set of signals in the IH NMR spectrum. The key IH NMR 
diagnostic signals are that of the two-proton singlet for the terminal methylenic 
protons at ~ 8 6.60 TJPm, and the doublet for the hydroxyl group at ~ 82.00 ppm. 
CHO OR 
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Table 1. Table showing substituents (R) from B-H adducts and their synthetic yields 
Entries Compound R Product Yield % 
1 18 48 
."~ /=\ .~~ , 




3 22 ..s<. N/ 
~ "-
80 
4 23 ~-o 15 
5 24 rD 26 
~ 
6 25 13 10 ~ II 
3.1.1.2 Synthesis of Class 2 compounds 
Compound 19 was synthesized by deprotection of the tert-butyl ester 18. The 
reaction was carried out using a 1: 1 mixture of TF A and CH2Ch at 25°C, TLC 
analysis showed the:eaction was complete after 30 min. The product was isolated in 
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Scheme 4. Reagents and conditions: (a) 1 equiv. of TFA, CH2CI2, 25°C, 15 min, 97%. 
The ethanolamine and ethylene diamine-derived quinoline alcohol 57a and amine 
57b, intennediates (Scheme 5&6) required for the synthesis of the corresponding 
acrylates and amides respectively, were prepared by reacting the amine precursor with 
4,7-dichloroquinoline as described in the literature [26]. Work-up of the reaction and 
extraction with EtOAc followed by purification (by column chromatography) 




















A facile preparation of compounds 27 and 26 using commercially available PS-EDC 
was found to be a convenient route for coupling of arnines with the carboxylic acid 
[27] . PS-EDC is a polymer-supported activating agent, which works on the same 
principle as dicyclohexyl carbodimide (DCC). Activation of the carboxyl moiety 
results in the immobilization of the acid onto the polymer surface of PS-EDC. 
Reaction of this activated polymer-bound carboxyl with arnines results in the 
displacement of the PS-EDC with concomitant release of the product. An initial 
attempt was made 10 convert the carboxylic acid to the corresponding acid chloride 
followed by reacting with the amine [26J. Results using this method were 
unsatisfactory and hence the application of PS-EDC. The polymer-assisted synthesis 
using this supported coupling agent has various advantages including the ease of 
separation of the s~pported species from a reaction mixture by filtration and washing 
(Scheme 7). Table:2, summarizes the chemical yields. 
OH HO R 
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Table 2. Table showing substituents (R) from the product and their synthetic yields 
Entries Compound R Product Yield % 
1 27 
2 26 
3.l.1.3 Synthesis of Class 4 compounds 
The synthesis of compounds 54 and 55 was first carried out by reacting commercially 
available p-toluenesulfonamide with an aldehyde in the presence of acetic acid in 
catalytic amount and methanol as a solvent to form the corresponding sulfonylimine, 
Scheme 8. The 'H NMR of the product showed only traces of impurities and 
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Scheme 8. Reagents and conditions: (a) 1 equiv. of aldehyde, MeOH, 50-70 aC, 
17hrs. 
A mixture of sulfonylimine, acrylate and D ABCO was stirred at room temperature for 
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Scheme 9. Reagents and conditions: (a) 1 equiv. of aldehyde, MeOH, Acetic acid, 50-70 aC, 











Alternatively, a one-pot protocol was adapted, involving the reaction of aryaldehydes 
(1 equiv.), acrylic acid 2-(7-chloro-quinolin-4-ylarnino)-acrylic acid ethyl ester/ 
acrylonitrile (3 equiv.), ill the presence of p-toluenesulfonarnide and 
triphenylphosphine in 2-propanol as a solvent [Z8] Scheme 10. Table 3. 
Scheme 1 O. Reagent~ and conditions: 1 equiv. of Arylaldehyde, 5 equiv. of ester! acrylonitrile, 
1 equiv. of p-toluenesulfonamide, 0.005 equiv. of PPh3 and 2-propanol. 
Table 3. 
Entries Compound # Aldehyde X Product 
yield (%) 
0 
























It was found that a one-pot three component aza-Baylis-Hillman reaction of 
arylaldehydes, acrylonitrile/ester and p-toluenesulfonarnide can be achieved using 
PPh3 in isopropanoL Yields ranging from 48-72% were obtained using variously 
substituted arylaldehyde. Better yields were obtained when tert-butyl acrylate was 
used (entry 1). 
3.1.1A Synthesis of Class 5 compounds 
The starting point for the synthesis of Class 5 compounds was the preparation of the 
acrylic ester 56 from the corresponding alcohol and acryloyl chloride in the presence 
of E13N using CH2Ch as a solvent [29] Acrylate 56 was then treated with respective 
aldehydes in the presence ofDBU to give compounds 48-53 in highly variable yields. 
The variable yields were due to incompleteness of the reaction. 
a 
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Scheme 11. Reagents and Conditions: (a) 1 equiv 2-(7-Chloro-quinolin-4-ylamino)-ethanol , Et3N, CH2CI2, 
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3.1.2 Support Bound reagents as potential catalysts for the B-H reaction 
When using an amine catalyst, one of the major drawbacks of the B-H reaction is the 
extra aqueous work-up step required at the end to remove the amine from the reaction. 
It is desirable to avoid this step by using support-bound catalysts [30l such as those 
based on BEMP (58), PTBD (59), Hunigs base (60), DMAP (61), and KF-Ah03, 
which can be conveniently removed by filtration. There have been previous 
unsuccessful attem{lts at using polymer-bound phosphorus-based catalysts [3\l . 
~N~') 
\-N 




Figure 9. Polyme:r supported bases 
For exploratory studies BEMP (58) was chosen, even though it is strongly basic and 
non-nucleophilic, because it has been used extensively in various contexts [3\] PTBD 











supported Hunigs base is a tertiary amine resembling triethylamine, which has also 
been successfully used in B-H reactions [33] On the other hand PS-DMAP is a 
nucleophilic base chosen due to literature precedence concerning the use ofDMAP in 
B-H reaction [34]-[35]. KF-Ah03 was chosen because it has been reported to be useful 
in catalysing Michael addition and other reactions [36]-[37] 
The results of catalyst screemng are summarized in .Tables 5-9. Initial catalyst 
screening experiments were performed using 4-quinoline-carbaldehyde with tert-butyl 
acrylate in acetonitrile as a solvent [38]. The results are presented .in Table 5. 
° AX 
[I ° a + 
Hoh ox 
I ° " CO'"--':: I ~ , /. N 
Scheme 3. Reagents and conditions: (a) 1 equiv. of aldehyde, 5 equiv. t-Butyl 




















Catalyst Reaction time (hrs) Aldehyde: acrylate: catalyst Product Yield (%) 
58 16 1 : 3 : 1 5 1 
59 16 1 : 3 : 1 47 
KF-Al203 16 1 : 3 : 1 40 
60 16 1 : 10: 1 0 
61 16 1 : 10: 1 0 
In this preliminary study BE"Ml> was surprisingly found catalyze the reaction. 
However, one significant drawback in the BE"Ml>-mediated reaction was the undesired 
formation of a self-aldol condensation by-product from the initial aldehyde [19]. No 
by-products were observed in the case ofPTBD and KF-Al203, which also showed 
catalytic activity. Coupled with the low cost, KF-Al203 was selected for further 
studies along with BE"Ml>, which was available in large quantities. Results are 














II 0 + a 
o II Ii) 
x~ o OH N02 
Scheme 13. Reagents and conditions: (a) 1 equiv. of 2-nitro-benzaldehyde 5 
equiv. t-Buty: acrylate, DBU 
Optimisation of catalyst loading and reaction time. 
35 
Entries Catalyst Reaction time Mol. Ratioa Product Yield % 
1 58 16 1 : 1 : 0.1 23 
2 58 16 1 : 1 : 0.3 33 
3 58 16 1 : 1 : 0.5 47 
4 58 16 1 : 1 : 1 51 
5 58 16 1 : 1 : 3 54 
6 58 16 1 : 3 : 1 65 
7 58 16 1 : 10: 1 69 
8 KF-Ah03 23 1 : 1 : 0.5 35 
9 KF-Ah03 23 1 : 1 : 1 38 
10 KF-Ah03 23 1 : 1 : 3 40 
11 KF-Ah03 18 1 : 3 : 1 55 
12 KF-Ah03 18 1 : 10: 1 57 
a : ratio of aldehyde: acrylate: catalyst 
In the case ofBEMP and KF-Ah03, decreasing the catalyst loading from 1 to 
0.1 mol. ratio resulted in the reduction of the product yield when the acrylate is kept 











In an attempt to eliminate by-product formation in the BEMP-catalyzed reaction, the 
effect of varying temperatures on the product yield was studied [16] . The reaction was 
performed at varying temperatures for 16 h. Results are presented in Table 7. 
Table 7. Optimisation of reaction temperature. 
Entries Catalyst Mol. Ratio Time Temperature (DC) Product Yield 
1 58 1 : 3: 1 16 0 30 
2 58 1 : 3: 1 16 25 65 
3 :38 1 : 3: 1 16 40 54 
4 KF-Ah0 3 1 : 3: 1 16 25 53 
5 KF-Ah03 1 : 3: 1 16 40 49 
It was noted that the optimum yields of product (65 % and 53%) were obtained when 
the reaction was performed at room temperature and a reaction time of 16 hrs (entry 2 
and 4, Table 7). 
Next the effect of solvent using a common aldehyde, o-nitrobenzaldehyde in t-Butyl 
acrylate and BEMP was studied. The results are shown in Table 8. From this brief 
study, acetonitrile and dichloromethane emerged as suitable solvents (entries 1 and 2), 
Surprisingly, little to no product was obtained when tetrahydrofuran and isopropanol 











Table 8. Assessment of the effect of solvent on the reaction. 
Entries Solvent Catalyst Product Yield % 
1 Acetonitrile (anhydrous) 58/KF-Ah03 64/45 
2 Dichloromethane KF-Ab03 53 
(distilled) 
3 Tetrahydrofuran 58/KF-Ab0 3 No reaction 
(anhydrous) 
4 Isopropanol 58/KF-Ah~ 34 / no reaction 
5 1,2-dichloroethane 58 No reaction 
Studies aimed at optimizing reaction conditions by investigating the effects of 
changing the acrylate (39] on the yields of the reaction were also undertaken. Structural 
variants of acrylates may provide stereo or stereoelectronic effect to stabilize the oxy 
anion intermediate and subsequently accelerate the reaction. Results are presented in 
Table 9. Prior to this study the necessary acrylates had to be synthesised in 
appropriate cases. Most acrylates were synthesized directly from commercially 
available acryloyl chloride and the corresponding alcohols. The results of the 
reactions of various acrylates are presented in Table 9. 
o 
a ~ II OR 











Table 9. Effect of the nature of acrylate 
Catalyst 
+ 
Entries R Catalyst Ratio Yield (%) 
1 Me 58 1 : 3 : 1 60 
2 Me KF-Ah03 1 : 3 : 1 46 
3 tert-Bu 58 1 : 3 : 1 65 
4 tert-Bu KF-Ah03 1 : 3 : 1 51 
5 Ph 58 1 : 3 : 1 25 
6 Bn 58 1 : 3 : 1 36 
7 I-naphthyl 58 1 : 3 : 1 20 
Overall the yields obtained in these reactions were poor to moderate. With 58 as 
catalyst, the best yields were obtained with tert-butyl and methyl acrylates (entries 3 
and 1), with yields in case of phenyl, benzyl and I-naphthyl acrylates somewhat 
poorer. The tert-butyl and methyl acrylates also contributed to moderately good 
yields when KF-AL203 was used as catalyst (entries 2 and 4). 
At this point, ultrasound was considered as an option for accelerating the reaction. It 
has been reported that the use of La(OTf)3 as a co-catalyst and ultrasound provides up 
to a 40 fold increase over the use of DAB CO alone [40]-[42], especially when aromatic 
aldehydes are usee. as electrophiles [43] The effect caused by ultrasound is due to the 











contribute to produce an acceleration of the reaction rate. Table 10, shows the results 
obtained by efforts to accelerate the reaction using ultrasound. 
Table 10. Effect of the ultrasound 
Entries Condition Ratioa Reaction time (hrs) Co-catalyst Yield (%) 
1 Ultrasound 1 : 3 : 1 6 
2 Ultrasound 1:3 : 1 6 LiClO4 
3 Stirring 1 : 3 : 1 6 LiClO4 
4 Shaking 1 : 3 : 1 6 
a : ratio of aldehyde: acrylate: catalyst 
All reactions were carried out with the ultrasonic bath temperature carefully 
monitored between 35-40 0c. The reaction was TLC monitored after each hour. In 
order to compare all the reactions under the same experimental conditions, the 
reaction was stopped after 6 h. The presence of co-catalyst LiCI04 appears to not 
affect the yield of the reaction when ultrasound is used or when the reaction is stirred 
(entries 1-3). In the absence of co-catalyst LiCI04, shaking is ineffective in 
promoting reaction whereas the use of ultrasound does result in the moderate yields of 
product. 




















In order to further detennine the scope and limitation of the B-H reaction catalysed by 
BEMP and KF-Ah03, the reaction was extended to other aromatic aldehydes under 
optimum conditions [46]-[47] These results are presented in Table 11 . 4-quinoline 
carbaldehyde and 2-nitrobenzaldehyde are included in the table for companson 
purposes. Most of these aldehydes were commercially available from sigma-aldrich 
except for aldehydes 62, 63 and 64, which were synthesised as shown in Scheme 15 . 
A solution of 2,4-dihydroxybenzaldehyde, pyridinium p-toluenesulfonate and 3,4-
dihydro-2H-pyran in dry DCM was stirred for 48hrs at room temperature [48] The 
reaction mixture was washed with 1 M sodium carbonate and concentrated to give 62. 
Compound 63 was synthesised by suspending 62, NaOH and CH31 in DMSO and 
stirring at room temperature for 1 hr. Removal of the THP protecting group from 63 
using 4 M HCl afforded 64 . 
. 
N "" OH 
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62 63 64 
Scheme 15. Reagents and conditions: (a) 3,4-Dihydro-2H-pyran, CH2CI2 , RT, 96% ; (b) CH31, NaOH, 











Table 11. Baylis-Hillman reaction of tert-butyl acrylate with different aldehydes 
catalysed by support-bound bases. 
Entries Aldehyde Catalyst Ratio Product yield (%) 
CHO 
00 ~ .--: 
1 N 581KF -Al20 3 1 : 3 : 1 51 / 48 
J? OHC ~ 
N02 
2 58/KF-Ah03 1 : 3 : 1 65 / 53 
3 
q OH 








OHC I ~ 58 1 : 3 : 1 65 
OH 
6 D OHC ~ 58 1 : 3 : 1 53 
7 
q0l) 










































Catalyst Ratio Product yield (%) 
581KF -Al203 1 : 3 : 1 60/41 
581KF -Al20 3 1 : 3 : 1 63 / 45 
581KF-Al20 3 1 : 3 : 1 65 
58 1 : 3 : 1 45 
1 : 3 : 1 46 
1 : 3 : 1 32 
581KF-Ab03 1 : 3 : 1 56 / 52 










Entries Aldehyde Catalyst Ratio Product yield (%) 
16 
/O~CHO 




58/KF -Al20 3 1 :3:1 58/41 
N02 
18 58/KF-Al203 1 : 3 : 1 63/50 
19 58 1 : 3 : 1 15 
20 58 1 : 3 : 1 26 
21 0) 58 1 : 3 : 1 10 h O/. 
o~ 
H 











Many aromatic aldehydes and branched aliphatic aldehydes are reluctant to serve as 
substrates, the major drawback being the slowness of the reaction. However in this 
study the main emphasis was given to aromatic aldehydes. The investigation involved 
aldehydes without any substituents on the aromatic ring, substituents with electron 
donating groups (entries 3, 4 and 5) and substituents with electron-withdrawing 
groups (entries 2, 8, 9, 10, 11 and 12). As shown in Table 11, both aliphatic (entries 
19-22) and aromatic aldehydes (entries 1 ~ 18 & 23) were converted to their 
corresponding B-H products in yield range 10-65 %. However, it is not clear which 
substitution pattern on the aromatic ring could be successfully used to achieve better 












BIOLOGICAL RESULTS AND DISCUSSION 
4.1 Activity of selected compounds against cruzain and T. cruzj 
The data in Table 12 shows the activity of selected derivatives (Figure 10) with 
respect to inhibition of the enzyme cruzain. 
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The assays were perfOlmed at the University of California San Francisco, USA. All 
of the compounds were tested against 4nM cruzain by incubating them with the 
enzyme for 5 minutes and then adding substrate. Three concentrations of each 
inhibitor were tested: 10, 1 and O.l~. The ICso, which is defined as the 
concentration of inlubitor decreasing substrate hydrolysis by 50%, was determined. 
The results are shown in Table 12. The data for standard control drugs K777, a vinyl 
sulfone and Kl102 an acyl hydrazine is included partly for comparison purposes. 
Figure 11. However, since the controls belong to two totally different aforementioned 
classes of compounds, they cannot be compared directly with the compounds in Table 
12, which are Baylis-Hillman adducts. Their inclusion mainly serves the purpose of 
confirming the reproducibility of the assay over a time period. 
0 ,----











Table 12. Inhibition of cruzain. 
Entries Compound lC50, ~ 
Kl102 0.002-0.01 
2 K777 0.07-0.3 
" 18 » 10 .J 
4 19 » 10 
5 21 » 10 
6 22 » 10 
7 26 »10 
8 42 2.8 
9 51 » 10 
10 56 » 10 
As seen from Table 12 there is no evidence that the compounds were acting against 
cruzain except for compound 42 (Entry 8), which showed an 1C50 value of 2.8 )lM. 
Based on the activity of compound 42, future work should further include the 
synthesis of aza-B-H adducts with substrates varied between different acrylates, 











4.1.1 T. cruu in culture 
T cruzi survival or death within the oxidative environment generated by activated 
macro phages depends on the capacity of the parasite to cope against the cytotoxic 
potential of the compound being tested. Figure 12 shows activity of selected 








Inhibitor ID NM40 
Compound 22 
K NM NM NM NM NM NM NM NM 
777 40 35 31 25 22 19 06 04 
Inhibitor 10 
NM35 NM31 NM25 NM22 NM19 
26 42 57 21 56 
NM06 
19 
T cruzi-infected mammalian cells treated with 42 survived more than 40 days in 
culture as compared to 5 days for their untreated counterparts at a concentration of 5 
11M. This concentration is even lower than that for the control (K777) that is 
normally used at 1 G 11M. 
Since K777 is a potent inhibitor of cruzain, and T cruzi-infected cells survive more 













suggests cruzain may not be the primary target for 42. The cell culture activity 
involves complicated factors. Compounds that are potent inhibitors of cruzain in vitro 
are not necessarily active in cell culture. Compounds must be able to cross the 
macrophage's cell membrane and cross the parasite's cytoplasm in sufficient quantity 
to significantly inhibit cruzain without killing the host celL In view of this, compound 
42 may possess the requisite transport properties to reach its targets, including 
cruzam. 
4.2 Activity of selected compounds against Falcipain-2, W2 and Trypanosoma 
brucei. 
A senes of compounds (Figure 13) was tested against falcipain-2 and W2, a 
chloroquine resistant strain of P. ja!ciparum, the causative agent of malaria Activity 
of the compounds against cultured malaria parasite was determined and their ICso 
values reported in Table 13 . Selected compounds were also screened for inhibition of 
Trypanosoma brucei, the causative agent of Mrican sleeping sickness. The 50% 
effective dose value (EDso), i.e. the inhibitor concentration necessary to reduce the 











X= t-Butyl acrylate 
n:c",= c, 48: AI= II ' I /. ~N CI 
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Figure 13. 
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Table 13. Activity against chloroquine resistant strain (W2), Falcipain-2 and T 
brucei. 
Entries Compound W2 1C50 ().lM) Falcipain-2 1C50 ( ~M) T brucei ED50 ().tM) 
1 18 >10000 >10 ND 
2 19 > 10000 >10 ND 
3 21 0.197 >10 ND 
4 22 > 10000 >10 ND 
5 26 >10000 >10 ND 
6 27 NDa ND ND 
7 56 >1000 >10 ND 
8 42 >1000 2 ND 
9 44 NO ND 3 
10 43 ND ND >10 
11 45 2.417 ND >10 
12 47 ND ND >10 
13 49 NO ND >10 
14 50 1.597 ND 4 
15 51 0.171 > 10 ND 
16 52 1.597 > 10 >10 
17 53 ND ND > 10 











As shown in the table only compounds 21, 45, 59, 51 and 52 generally showed 
activity (albeit modest) against the W2 strain. With the exception of 42, compounds 
did not have an effect against falcipain-2, at the cut-off concentration of 10 j.iM. Lack 
of correlation between the antimalarial activity of 21, 51 and 52 and inhibition of 
fa1cipain-2 suggests that falcipain-2 is not the target. The food vacuole abnormality 
that should accompany toxicity due to falcipain-2 inhibition was not seen even at high 
concentration. Antimalarial activity is probably due to inhibition of other unknown 
targets. When tested against T. brucei, compOtmds 44 and 50 exhibited EDso values 
of <10, whilst the EDso values of other compounds were greater than 10 /.lM, 
suggesting these two compounds to be moderately active. 
Due to factors beyond our control, some compounds were not tested within the time 












The potential use of KF -Ah03, PTBD and BEMP as support-bound catalysts for the 
B-H reaction was demonstrate. For most cases moderate yields were obtained. 
Further studies are required in order to improve the reaction rate and chemical yields. 
2-[quinolin-4-yl-(toluene-4-sulfonylamino )-methyl]-acrylic acid tert-butyl ester, 42 
showed the most promising result as a potential antitrypanosomal agent and forms a 
. basis for the synthesis of other aza- B-H ad du cts, with the substrates being varied 
between different acrylates, aldehydes and sulfonamides as part of structure-activity 
relationship studies. including the synthesis and biological evaluation of the 
respective enantiomers. The activity of 44 and 50 against rhodesain, the cysteine 
protease from T brucei, was not tested. This would have enabled a correlation to be 
made between the antiparastitic activity and inhibition of rhodesain. The activity of 













All reactions were monitored by TLC on 25 aluminium sheets silica gel 60 F254 
(MERCK) and visualised under ultraviolet light (254 nm) and either sprayed with 
anisaldehyde spray (freshly prepared from a 2.5% solution of p-methoxybenzaldehyde 
(20 cm3) and IBM sulphuric acid (lcm3) or cerium (IV) ammonium sulphate in 8M 
sulphuric acid, followed by heating at 200°C. Column chromatography was carried out 
using silica gel 60 (0.063- 0.200mm). 
Melting points were taken on a Fischer-John hot stage microscope melting point 
apparatus and are uncorrected. The IR spectra were obtained using a Mattson Instrument 
Satellite FTIR spectrometer (potassium bromide disks and plastic films). The IH NMR 
spectra were recorded on either a Varian VXR-200 at 200MHz, Varian Mercury 
300MHz or Varian Unity spectrometer (400MHz) and chemical shifts (8) are in ppm 
relative to internal tetramethylsilane (TMS). 13C 1\i""MR spectra were recorded on the 
same instruments operating at 50, 75, 100 MHz respectively. Elemental analyses were 
performed using a Fisons EA 1108 CH-~ instrument. Mass spectra were recorded on a 
VG micromass 16F spectrometer operating at 70eV with an accelerating voltage of 4kV. 











The following numbering system was used to assIgn aromatic protons in the proton 
nuclear magnetic resonance spectra of compounds based on quinoline moieties. 
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5.2 General method for the preparation of targets 18, 21, 23, 24 and 25 
A mixture of 4-quinoline-carbaldehyde (3mmol), ester (0.66ml) and 
DBL' (0.45ml) was stirred at room temperature for 16h. The reaction mixture was 
purified by column chromatography yielding an ester. 
Esters used: I-Butyl acrylate (O.5125g, 3mmol), Acrylic acid 2-(7-chloro-quinolin-4-
ylamino)-ethyl ester (0 .0853g, 0.3mmol), Acrylic acid phenyl ester (O.lg, 0.63mmol), 




~ ~ 0 
// /. 
N 2-(Hydroxy-quinolin-4yl-methyl)-acrylic acid tert-butyl ester. 
18 
Yield (0.45g, 50%) as white crystals; Rf 0.20 (3:7, EtOAc: Hexane); mp 120-130 °C; IR 
(CHCb) Vrnax 3611,3018,2410,1707 cm- I ; DH (300MHz; CDCh) 8.31 (lH, d, 1=8.4, H-
1), 8.16 (lH, d, 1=6.5, H-8), 7.93 (IH, d, 1=6.3, H-5), 7.60 (1H, m, H-7), 7.58 (lH, t, 
1=6.3, H-6), 7.24 (lH, d, 1=8.2, H-2), 6.65 (2H, S, C=CH2, H-11), 5.41 (lH, d,1=9.4, 
CHOH, H-IO), 2.04 (1H, d, 1=9.2, OH), 1.47 (9H, s, C(CH3)3); Dc(75.45 MHz) 162.2, 
150.4, 148.7, 145.4, 137.2, 130.3, 129.1, 127.0, 126.7, 123.7, 118.4, 76.6 and 28.03; 
LRMS (EI) mlz 285 (Mt; C17H I9N03 requires 285 .34; Calc. for C, 70.31; H, 7.01; N, 











HO o o~~i ~ 
/- \\ /; 
N 
CI Hydroxy-quinolin-4-yl-methyl)-acrylic acid 2-(7-
chloro-quinolin-4-ylamino )-ethyl ester. 21 
The residue was evaporated giving the product ester. Yield (0.073g, 89%) as brown 
gum;Rf 0.13 (0.5: 9.5 MeOH: CB2Ch); oH(300:MHz, CDCh) 8.35 (2II, m, B-1 and H-1), 
8.25 (lR, d, J= 8.5, H-8), 8.22 (2H, m, H-5 and H-8), 8.16 (III, rn, H-7), 7.95 (2H, m, 
H-5 and H-6), 7.93 (lH, d, J=8.2), 7.44 (III, m, H-2 and H-6), 6.65 (2II, s, C=CH2, H-
11), 5.19 (III, d, J=10.2, CHOH, H-10), 4.20, (IH, t, J=ll.4, NH), 3.90 (2II, t, J=11.0, 
OCH2), 3.32 (2H, q, J=11.2, CH2NH), 2.08 (III, d, J=10 .8, OH); oc(75.45 MHz) 165.2, 
157.2,149.1,148.1,145.7,145.3,132.8,131.7,130.6, 129.7, 128.7, 126.4, 124.2, 124.0, 
122.8, 118.5, 118.0, 117.6, 84.0, 72.5 and 69.0; LRMS (El) mlz 434; C2Ji2oN303Cl 












2-(Hydroxy-quinolin-4-yl-methyl)-acrylic acid phenyl ester. 
23 
Yield (0.032g, 16%) as brown oil. Rf 0.1 (4:6 EtOAc: Hexane); oH(300MHz, CDCh), 
8.25 (lH, d, J=l.O, H-l), 8.10 (1H, d, J= 4.6, B-8), 7.88 (lH, d, J=4 .8, H-5), 7.71 (lB, m, 
H-7), 7.53 (1H, t, J=4.4, H-6), 7.30 (1H, d, J=I.2, H-2), 7.11 (2H, dd, J=2 .6 and 9.2, Ar), 
7.09 (3H, In, Ar), 6.56 (2H, S, C=CH2, B-l1), 6.20 (lH, m, CHOH, H-I0), 2.3 (lB, m, 
OB); oc(75.45 MHz) 161.0, 142.1, 140.9, 140.6,140.4,128.6,128.5,128.2,128.0,71.2; 
HRMS (El) mlz 305, C19BlSN03 requires 305.33. 
HoAo~ 
CO~ o U I h i ~ 
N 2-(Hydroxy-quinolin-4-yl-methyl)-acrylic acid benzyl 
ester. 24 
Yield (0 .051g, 26%) as yellow oil; RfO.1 (4: 6 EtOAc: Hexane); OH (300rvrnz; CDCh) 
9.12 (lH, d, J=8.2, B-1), 8.50 (lH, d, J=4 .0, B-8), 8.42 (lB, d, J=4.0, B-5), 8.01 (lB, m, 
B-7), 7.95 (1H, t, J=4.2, H-6), 7.88 (lH, d, J=8.5, B-2), 7.65 (5H, ill, Ar), 6.40 (2H, S, 
C=CH2, B-l1), 5.80 (2B, s, OCH2), 5.19 (lB, d, J=I1.5, CHOH, H-10), 2.20 (lH, d, 
J=11.4, OB); oc(75.45 rvrnz) 165.2, 148.7, 145.4, 145.3, 142.1, 129.1, 128.8, 128.7, 












/ '\;, 0?J 
° --
/ ~ 2-(Hydroxy-quinolin-4-yl-methyl)-acrylic acid naphthalen-
l-ylmethyl ester. 25 
Yield (0.0048g, 10%) as brown oil; RrO.3 (4: 6 EtOAc: Hexane); bH (300:MHz; CDCh) 
8.84 (lH, d, J=6.5, H-1), 8.73 (lR, d, J=5.4, H-8), 8.01 (2H, m, H-5 and Ar), 7.78 (5H, 
m, Ar), 7.63 (2R, m, H-7), 7.52 (1H, d, J=6 .5, H-2), 7.50 ( IH, t, J=5.3), 7.48 (1H, m, 
Ar), 6.68 (2R, s, C=CHz, H-11), 5.48 (2H, s, OCHz), 5.46 (1R, d, J=l1.6, CHOH, H-10), 
2.48 (lH, d, J=l1.4, OFf); bc(75.45 NIHz) 165.4, 152.3, 150.1, 149.6, 149.5, 135.3, 
135.2, 129.0, 128.8, 128.7, 128.5, 128.4, 128.1, 127.6, 127.4, 119.4, 119.1 and 72.3; 
HRMS (El) m/z 369.38741 ; CZJi19N03 requires 369.41 
5.3 Procedure for the preparation of target compounds 22,26 and 27 
5.3.1 Preparation procedure of an acid 
OH 
2-(Hydroxy-quinolin-4yl-methyl)-acrylic acid. 19 
Trifluoroacetic acid (1 equiv.) was added to 2-(Hydroxy-quinolin-4yl-methyl)-acrylic 
acid methyl ester (4 mmol) in CHzCh. The reaction mixture was stirred at room 
temperature with TLC monitoring after 15min. After completion, the solvent was 
evaporated off and excess IF A removed by co-evaporation with cyclohexane to yield an 











IR (CHCb) Vrnax 3850, 3742, 2799, 1740 em-I; oH(300MHz, CDCb), 9.15 (Ill, s, 
OHC(O», 8.33 (IH, d, J=3.0, H-l), 8.31 (lH, d, J=5.4, H-8), 8.04 (lH, d, J=S .2, H-S), 
7.8 (lH, m, H-7), 7.S8(lH, t, J=5.S , H-6), 7.83 (IH, d, J=3.2, H-2), 6.56 (2H, S, C=CH2, 
H-l1), 5.61 (lH, d, J=1 1.7, CHOH, H-10), 2.25 (lH, d, J=11.3, OR); oc(75A5 N1Hz) 
167.9, 148.3, 144.1, 133 .5. 129.5, 128.6, 126.5,69.0 and 50.0; LRMS (EI) mlz 229 (M) ; 
C13H I1N03 requires 229.07. 
5.3.2 Procedures for the starting materials 
2-(7-Chloro-quinolin-4-ylamino)- ethanol. 57 a 
A mixture of 4.7 dichlo[,Jquinoline (1.987g, 10 mmol), alcohol (20 equiv.), EbN 
(0.3 equiv.) and K2C03 was heated for Ih at 80 °C with stirring. It was then heated at 
135-140 °C for 4 h with continuous stirring to drive the reaction to completion, and there 
after cooled to room temperature. The reaction was left at room temperature for 2 hrs to 
crystallize out of the solution. The product was recrystalised in methanol giving an 
alcohol (0.88g, 41 %) as white powder. Rf (1:9 MeOH: CH2Ch) 0.13; mp 206-208; IR 
(Nujol) Vrnax 3618,3029, 1534, 1392 em-I; OH (400MHz; CD30D) 8.04 (lR, d, J=4.0, H-
1), 7.98 (lH, m, H-8), 7.71 (lR, d, J=3 .6, H-5), 7 .39 (IH, d, J=3.2, H-6), 7.24 (Ill, d, 
J=4.3, H-2), 4.02 (lH, t, J=9.8, NH), 3.70 (2H, q, J=9.2 , CH2NH), 3.50 (2H, m, 
CH20H), 2.15 (lH, rn, OR); oc(75.45 MHz, CDCb) 151A, 149.5, 149.0, 134.6, 128.1 











N- (7-Chloro-quinolin-4-yl)-ethane-l,2- diamine.57b 
A mixture of 4.7 Dichloroquinoline (lOmmol) and ethylenediamine (4ml) was heated for 
1h at 80°C with stirring. It was then heated at 13 5-140 °C for 4 hrs with continuous 
stirring to drive the reaction to completion, and there after cooled to room temperature. 
NaOH (IN, 20rnl) was added followed by heating to 40°C for 10rnin. Thereafter ethyl 
acetate (125ml) was added followed by warming to 35°C for 1h and cooling to room 
temperature. The organic layer was separated from the aqueous phase, washed with 
water and was dried over sodium sulfate (anhydrous) and the solvent was evaporated off 
to obtain offwhite crystals (1.709g, 77%). mp 124-127 °C; Rf 0.34 (1:9 MeOH: CH2Ch); 
OH (400MHz; CD30D) 8.19 (lH, d, J=5.4, H-l), 7.88 (1H, m, H-8), 7.49 (lH, d, J=6.2, 
H-5), 7.20 (1H, d, J=5.1, H-2), 7.16 (1H, d, J=6.0, H-6), 4.6 (lH, t, J=9.6, NH), 3.32 (2H, 
q, J=10.5, NHCH2), 3. 1 (2H, m, CH2NH2 ), 2.4 (2H, m, NH2); oc(75.45 MHz, CDCh) 
151.6, 151.2, 148.5, 135.2, 126.4, 124.9, 123.2, 117.7, 98.6, 53.6, 44.6, 39.5; 
CllH12C1N3 requires; Calc. for C, 59.60; H, 5.46; Cl, 15.99; N, 18.95 Found C, 59.30, H, 










5.3.3 General procedure for preparation of 22 and 26 
HO U R yy 
~ O 
~~I) 
N To a suspenslOn of PS-EDC (1.2mmol) In chloroform (lOml) 
amine/alcohol (0.45mmol) and acid (0.54mmol) were added. After the reaction was 
shaken overnight at room temperature, the mixture was filtered. The resin was washed 
with chloroform (3 x 8ml), and the combined filtrate was evaporated to dryness. The 
crude was purified using column chromatography. 
Alcohol used: 3-Dimethylamino-propan-l-ol (0.2g, 0.87mmol) 





N 2-(Hydroxy-quinolin-4-yl-methyl)-acrylic acid 3-
dimethylamino-propyl ester. 22 
Yield (0.22g, 80%) as brown oil; Rf 0.17 (2:8 MeOH: CH2Ch); oH(300MHz, CDCb) 
8.85 (2H, m, H-l and H-8), 8.16 (lH, d, J=2 .0, H-5), 8.15 (lH, TIl, H-7), 7.65 (lH, t, 
J=2.3, H-6), 7.62 (IH, m, H-2), 6.20 (2H, S, C=CH2, H-l1), 5.45 (IH, ill, CHOH, H-I0), 
4.27 (2H, t, J=12.5, OCH2), 2.93 (2H, t, J=12 .3, CH2N), 2.65 (6H, s, N(CH3)2), 2.15 (1H, 
ill, OH), 1.4 (2H, m, CH2); oc(75.45 MHz) 167.0, 150.3, 150.1, 144.7, 130.0, 129.6, 
129.1, 128.9, 127.5, 126.7, 126.3, 123 .8, 119.0, 77.2, 68.2, 58.7, 43.0 and 29.6; LRMS 
(EI) mlz 314; ClsH22N203 requires 314.38; Calc. for C, 68 .77; H, 7.05; N, 8.91; Found 











N- [2-(7 -Chloro-q uinolin-4-ylamino )-ethyl]-2-
(hydroxy-quinolin-4-yl-methyl)-acrylamide. 26 
Yield (0.083g, 43%) as yellow oil. Rf 0.45 (2:8 MeOH: CH2Ch); DH(300MHz, CDCb) 
8.50 (2B,m, B-1 and H-l), 8.2 (1H, d, J=9.3, NHC(O)), 8.01 (4H, m, B-8, B-8, B-5 and 
B-5), 7.95 (4H, m, B-2, H-6 and B-2 and B-2), 6.25 (2H, S, C=CH2, B-l1), 5.64 (lH, d, 
J=13 .9, CHOH, H-10), 4.25 (1H, m, NH-Ar), 3.48 (2H, t, J=9 .9, NHCH2), 3.17 (2H, q, 
J=9.6, CH2NH) , 2.19 (1H, d, 1=14.0, OH); Dc(75.45 MHz) 166.0, 154.6, 149.2, 145.3, 
145.1,144.9,144.7,144.3,129.7, 126.8, 125.4, 125.2, 119.8,119.7,119.4,115.4,77.42, 
38.89 and 33.25; LRMS (El) mlz 433; C2JI21CIN402 requires 432 .90. 
5.4 General procedure for the preparation of ester acrylates 56 
o 
~OR 
II A solution of acryloyl chloride (1.9 mmol) in CH2Ch (5ml) was cooled in an ice 
bath. Alcohol (4.6 mmol) was added to the cold solution, and then a solution of redistilled 
E1JN (0.5ml) in CB2Ch (1.25ml) was added dropwise and stirred for 1 hr. The product 
was purified by column chromatography and an ester was obtained. 
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CI Acrylic acid 2-(7-chloro-quinolin-4-ylamine)-ethyl ester. 56 
Yield (1.320g, 37%) as yellow powder; Rf 0.35 (1:9 MeOH: CH2Ch); mp 78-79 °C; IR 
(CHCb) Y rnax 1721, 1514 cm-
I
; OR (400MHz, CDCb) 8,96 (lH, d, J=4.4, H-l), 8.18 (1H, 
s, H-8), 7.71 (2H, m, H-6 and H-5), 7.31 (1H, d, J=4,5, H-2) , 6.40 (2H, d, J=9.2, 
CH=CH2, H-ll), 6.25 (lH, t, J=9.0, CH=CH2), 4.40 (2H, d, J=14.1, OCH2), 4.00 (IH, t, 
J=13.9, NH), 3.56 (2H, q, J=14.2, CH2NH); oc(75 MHz) 165.5, 152.0, 150.3, 147.1, 
13l.4, 131.2, 129.1, 127.4, 124.1, 120.9, 63.4, 62.3, 48.6, 30.9; LRMS (El) mlz 276 
(Mt, C1JI13CIN20 2 requires 276.72, Calc. for C, 60,77; H, 4.74; Cl, 12.81; N, 10.12; 
Found C, 61.32; H, 4.21; N 7.87. 
o 
{o-{ > Acrylic acid phenyl ester. 
Yield (0.3139g, 50%) as white powder; Rf 0.37 (1:9 MeOH: CH2Ch); mp 56-59°C; OR 
(300MHz; CDCb) 7.33 (2H, rn, Ar), 7.28 (3H, In, Ar), 6.03 (IH, t, J=10.2, CH=CH2) , 
5.98 (2H, d, J= 10.7, CH=CH2 ); oc (75.45 MHz) 165.0, 135.9, 131.0, 128.5, 128.3, 128.2, 












{OU Acrylic acid benzyl ester. 
Yield (0.42g, 56%) as yellow powder; Rf 0.35 (3:7 EtOAc: Hexane); illp 68-70 °C Rf 
0.38 (1:9 MeOH: CH2Ch); 8H (300MHz; CDCb) 7.40 (5H, ill, Ar), 6.48 (III, t, J=11.7, 
CH=CH2), 6.22 (2H, d, J=11 .6, CH=CH2), 5.21(2H, s, OCH2); 8c(75.45 MHz) 165.9, 
135.9, 131.0, 128.5, 128.0, 76 .7, HRMS (El) mlz 162.06829 (~); ClOH lO02 requires 
162.06. 
o 
{OE Acrylic acid naphthalen-l-yl ester. 
(0.430g, 64%) as yellow oil; RfO.32 (1:9 MeOH: CH2Ch), 8H (300MHz; CDCh) 7.86 
(III, d, J=5.4, Ar); 7.48 (5H, ill, Ar); 7.26 (III, d, J=5.2, Ar), 6.42 (2H, d, J=13.2, 
CH=CH2), 6.03 (1H, t, J=13.5, CH=CH2), 5.92 (2H, s, OCH2); 8c(75.45 MHz) 164.8 , 
148.5, 134.0, 132.7, 131.6, 129.5, 128.1, 127.9, 126.7, 125.8, 121.2, 118.63; HRMS (El) 
mlz 212.06799 (~); C rJi1202 requires 212.06; Calc. for C, 78.77; H, 5.09; Found C, 











5.5 General procedure for the preparation of aldehyde. 62, 63 and 64. 
N°UO Hylr 
o OH 2-Hydroxy-4-(tetrahydro-pyran-2-yloxy)-benzaldehyde [47] • 62 
A solution of 2,4-dihydroxybenza!dehyde (l4.48 mmo!), pyridium p-toluenesu!fonate 
(0.S8 rnmol) and 3,4-dihydro-2H-pyran (23.17 mmol) in dry DCM (20 ml) was stirred for 
48 hrs at room temperature. The reaction mixture was extracted with dich!oromethane 
and the organic phases were washed with 1M sodium carbonate (20 ml) and concentrated 
under reduced pressure to give 62 (3.224g, 96 %) as pale yellow oil. Rf 0.2 (3: 7 MeOH: 
CH2Ch); OH (400M.Hz; CDCh) 11.34 (lH, s, HC(O», 7.34 (III, m, Ar), 6.66 (2H, m, 
Ar), 5.45 (lR, s, Ar-OH) , 3.60 (2H, t, J=11.5, OCH2), 1.82 (2H, t, J=11.8 CH2 ), 1.65 
(4H, m, 2CH2); 8c(7S.4S M.Hz) 194.S, 164.4, 164.1, 13S.2, 11S.7, 109.4, 103 .7, 96.2, 
62.9,62.1, 30.6 and 29.9. 
N
~ 0"-0 
H I // 
I I 
o OMe 2-Methoxy-4-(tetrahydro-pyran-2-yloxy)-benzaldehyde (47). 63 
62 (9.6 mmo!), NaOH (20.1 mmo!) and CH31 were suspended in DMSO (IS ml), stirred 
for 1hr at room temperature and then added to water (60 ml) . The reaction mixture was 
extracted with DCM (3 X 100m!) and the combined organic phases were washed with 











7 MeOH: CH2Ch); bH (400.MHz; CDCh) 11.34 (lH, s, HC(O»), 7,34 (lH, m, Ar), 6,66 
(2H, ill, Ar), 5,45 (1H, t, J=11.6 , OCH2), 3,69 (3H, s, OCH3) , 3.60 (2H, t, J=11.2, CH2), 
1.65 (4H, m, 2CH2); bc(75,45 .MHz) 194.5, 163.2, 163.1, 135.2, 115,7, 109,4, 103.7, 
96.2,62 .9, 62,1, 56,4, 30.6 and 30.2. 
HHOH 
o OMe 4-Hydroxy-2-methoxy-benzaldehyde [471. 64 
To a stirred solution of63 (5 .5 nunol) in ethanol (20 ml), 4M HCI (6 ml) was added, The 
resulting mixture was stirred for 15 min and then added to water (60 ml). The reaction 
mixture was extracted with EtOAc (3 X 100ml), washed with brine (l00 ml) and 
concentrated to give a residue, which was recrystallized from toluene to afford 64 
(1.130g, 0.89%) as pale green powder. Rf 0.15 (3 : 7 MeOH: CH2Ch); bH (400.MHz; 
CDCh) 10.1 (lH, s, HC(O), 7.65 (lH, m, Ar), 6.47 (2H, m, Ar), 4.78 (1H, s, OB), 3,88 
(3H, s, OCH3); bc(75,45 l\IfHz) 188.6, 165.9, 164,8, 158.1, 130,5, 127,9, 117,7 and 54.9. 
5.6 General procedure for the preparation of 48, 49, 50, 51, 52 and 53. 
Arylaldehydes (l equiv), acrylic ester (3 equiv.) in DBU (1 equiv,) were stirred at room 
temperature for 16 hrs. The product mixture was purified by column chromatography. 


















but-2-enyloxy)-phenyl]-methyl}-acrylic acid 2-(7-chloro-quinolin-4 -ylamino )-ethyl 
ester. 51 
(IH, d, J=2,7, H-l), 8,7 (IB, S, B-8), 8,5 (2H, Ill, H-5 and H-6), 7,97 (1H, d, J=2.6, B-
2),7.81 (lH, ill, Ar), 6.45 (2H, ill, Ar), 6,11 (2H, S, C=CH2 ), 5.45 (IH, ill, CHOH), 5.25 
(IH, d, J=102, CH=C), 4,60 (2H, t, J=10.5, CH20), 4.25 (2H, t, J=9.4, OCH2), 4,12 (1H, 
t, J=9.5, NH), 3.63 (3H, s, OCH3), 338 (2H, ill, CH2NH), 2.2 (lH, Ill, OH), 1.80 (6H, s, 
C=(CH3)2); oc(75.45 MHz) 165 ,5, 160.2, 158.4, 156,8, 148.8, 143.8, 138,6, 134.2, 128.5, 
125 .2, 123.0, 122.8, 122.4,98.5, 68.8, 68.2, 65.4, 54.3,26.2 and 20.0; HRMS (FAB) mlz 
2- [(2-Chloro-6-methyl-q uinolin-3-yl)-
hydroxy-methyl]-acrylic acid 2-(7 -chloro-quinolin-4-ylamino )-ethyl ester. 48 
Yield (1.420g, 67%) as; OH (400MHz, CDCh) 8.48 (lH, d, J=6,0, H-1), 8.10 (2H, ill, H-5 
and H-8), 7.92 (lH, d, J=6,2, H-8), 7,88 (2H, ill, H-5 and H-3), 7.43 (IH, d, J=6,0, H-7), 











(2R, t, J=1O .2, OCH2), 4.20 (2H, q, J=10.4, CH2NH) , 4.0 (1H, m, NH), 2.54 (3H, s, 
CH3), 2.0 (lR, s, OH); OC (75.45 MHz) 145 .9, 143 .2, 143 .0, 138.4, 138.3, 138.0, 128.2, 
128.0, 126.4, 126.3, 126.3, 123 .8, 123.4, 123 .0, 122.2, 121.4, 69.4, 55.6, 21.0; 
2- [(2,5-Dichloro-phenyl)-hydroxy-methyl]-
acrylic acid 2-(7-chloro-quinolin-4-ylamino)-ethyl ester. 50 
Yield (2.501g, 82 %) as; OH (400MHz, CDCh) 8.60 (IR, d, J=6 .2, B-1), 8.39 (lB, ill, H-
8), 8.28 (IH, d, J=6 .3, B -5), 8.23 (IH, d, J=6 .1, B-6), 8.18 (1H, d, J=6 .3, B-2), 7.23 (3H, 
m, Ar), 6.11 (IH, s, C=CHH, B-11), 5.98 (IH, s, C=CHH, B-11), 5.70 (1H, d, J=9 .3 , 
CHOB, B-IO), 4.11 (2H, t, J=I1.2, OCH2), 4.0 (lB, t, J=Il.7, NH), 3.93 (2H, m, 
CH2NH) , 2.34 (1H, d, J=9.4, OH); oc (75.45 MHz) 165 .S, IS9.6, lS6.8, IS3 .3, 148.7, 
148.6,147.9,145 .5, 140.6,129.7, 129.6,129.4, 125 .1, 122.1, 120.6, 119.7, 118.6, 118.S, 
71 .6, 56.6; C21B17ChN203 requires 451 .73 . 
OH 0 
H~ 
"'-':: "'-':: o~N ~N 
a .....: / \ 
N CI ~J 
\ 
CI 2-[(2-Chloro-6-methoxy-q uinolin-3-yl)-
hydroxy-methyl]-acrylic acid 2-(7 -chloro-quinolin-4-ylamino )-ethyl ester. 52 
Yield (l.150g, 64%) as . Rf 0.25 (1:9 MeOH: CB2Ch); OH (300MHz; CDCb) 8.98 (lR, d, 
J=4.4, B-1), 8.21 (IH, m, B-8), 7.73 (4H, ill, B-8, H-5, R-S and R-3), 7.45 (2H, ill, H-7 











CHOR, R-10), 4.4 (2H, m, OCH2), 4.2 (2R, q, J=13 .5, CH2NH), 4.0 (lR, t, J=13 .8, NH), 
3.8 (3R, s, OCH3) , 2.0 (lR, d, J=l1.1 , OH); oe (75.45 MHz) 165.1, 159.0, 155.5, 150.1, 
150.0, 149.8, 142.8, 136.4, 134.7, 131.4, 130.0, 128.5, 122.3, 121.8, 121.6, 68.6,66.7, 
F 
2- [( 4-Fluoro-3-nitro-phenyl)-hydroxy-methyl]-
acrylic acid 2-(7-chloro-quinolin-4-ylamino)-ethyl ester. 49 
Yield (2.43g, 92%) as; OH (400MHz; CDCh) 8.96 (lR, J=4.4 , H-1), 8.18 (IR, m, H-8), 
7.82 (lH, d, J=5.4, H-5), 7.80 (lH, t, J=5.6, B-6), 7.40 (1R, d, J=4 .3, B-2), 7.45 (2H, m, 
Ar), 7.32 (1R, td, 0.4 and 9.1, Ar), 6.42 (2R, ill, C=CH2, R-11), 5.27 (IR, ill, CHOR, R-
10), 4.40 (2R, t, J=9.4. OCH2), 4.0 (lB, m, NH), 3.6 (2R, q, J=9.7, CH2NH), 2.16 (lH, 
ill, Oli) ; oe (75.45 i\-1Hz) 165.1 , 152.2, 143 .8, 141.6, 140.0, 131.5, 130.0, 129.9, 129.4, 
129.3, 127.8, 127.6, 126.6, 124.6, 121.1, 106.3, 62.5, 58.4, 48 .8, 29.8 and 21.7 ; 
5.7 Synthesis of sulphonyl amines 54 and 55 
--O--#-N~Ar 
o General procedure for the preparation of sulphonyl imines 
Toluene-4-sulfonamide (3.8mmol) and 4-quinoline-carboxaldehyde (3.2mmol) were 











stirred at 50-70 DC for 17 h. To the reaction mixture chloroform (~1 Oml) was added 
followed by water. The organic layer was separated and the solvent evaporated off. 
Aldehydes used: Quinoline-4-earboxaldehyde (0. 130g, 0.76mmol) and 2-Methoxy-4-(3-
methyl-but-2-enyloxy)-,.benzaldehyde (0.08g). 
-0-9 ~ /; ~-N~ o I 
/N 
I 0 4-methyl-N-(quinolin-4-ylmethylene) benzenesulfonamide. 
54 
Sulfonamide product obtained as a brown solid (0.56g, 92%) as off-white crystals. IR 
Vrnax (CHCh) 2410, 1343, 1046 em-I; Rf 0.33 (3:7 EtOAc: Hexane); bH(400MHz, CDCb) 
9.20 (Ill, s, N=CH), 9.15 (Ill, d, J=7.4, H-l), 9.09 Oll, d, J=8.3, H-8), 8.89 (Ill, d, 
J=6.4, H-5), 8.65 (Ill, ill, H-7), 8.6 (IH, t, J=8.5, H-6), 8.22 (lH, d, J=7.3, H-2) 7.50 
(2H, d, J=6.0, Ar), 7.34 (2H, d, J=8.2, Ar), 2.36 (3H, s, CH3); bc(75.45MHz) 173.7, 
160.1, 148.2, 138.4, 138.5, 130.2, 129.2, 128.5, 127.6, 126.4, 28 .9; LRMS (El) mlz 
310.0; CI&HlSN02S requires 309.9; Calc. for C, 65.79; H, 4.55; N, 9.03; S, 10.33; Found 
















Yield (0.026g, 33%); Rf 0.32 (3:7 EtOAc: Hexane); oH(3.00MHz, CDCb) 8.21 (lH, s, 
N=CH) , 7.82 (2H, dd, J=9.4 and 2.0), 7.33 (2H, t, J=8 .0), 7.27 (lH, m), 6.46 (2H, m), 
5.26 (lH, t, J=11.6, C=CH), 4.81 (2H, d, J=11.8, OCH2), 3.88 (3H, s, OCH3), 2.42 (3H, 
s, CH3), 1.76 (6H, s, C(CH3)2); oc(75.45MHz) 188 .3, 165.5, 163 .6, 139.2, 130.7, 129.7, 
129.6, 127.7, 126.5, 119.0, 106.3,99.82, 98.68,76 .59,65.20, 55.58,21.48 and 18 .22. 
LRMS (El) mlz 373 ; C2oH23N04S requires 373.47, C, 64.32; H, 6.21; N, 3.75; S, 8.59, 
Found C, 64.75, H, 6.66, N, 3.33. 
5.8 General procedure for BH reaction 
A mixture of Aldehyde (O.3mmol), tert-butyl acrylate/ methyl acrylate (0 .66ml) and 
acetonitrile/ DCMJ isopropanol was stirred at room temperature in the presence of either 
58,59,60,61, DBU, DABCO or KF-Ah03 as catalyst. The reaction was ended after the 
allotted time by filtering with dichloromethane. The crude product was purified by 
column chromatography using ethyl acetate and hexane as the eluting solvent yielding an 
ester. 
omOH 
X 0 OH OH 2-[(2,4-Dihydroxy-phenyl)-hydroxy-methyl]-acrylicacid 
tert-butyl ester. 30 
Yield (0 . 122g, 65%) as brown oil; Rf 0.35 (3 : 7 EtOAC: Hexan~); OH (200MHz; CDCb) 
7.44 (lH, d, J=2.4, Ar), 6.53 (lH, m, Ar), 6.41 (lH, d, J=2.3 , Ar), 6.39 (2H, S, C=CH2, 











1.48 (9H, s, OC(CH3)); 8c(75.45MHz) 167.0, 160.2, 158.5, 129.6, 129.5, 129.3, 129.0, 
84.0,66 .2,29.4; HRMS (EI) mlz 266; C1JI180s requires 266.29. 
2-[Hydroxy-(2-nitro-phenyl)-methyl]-acrylic acid tert-butyl 
ester. 28 
Yield (0.051g, 55%) as, RfO.35 (3: 7 EtOAC-Hex); IR Vrnax 3452,2932,1709.1528 em-I; 
8H (300NlHz; CDCh) 8.31 (IR, m, Ar), 7.96 (2H, m, Ar), 7.55 (1R, m, Ar), 5.29 (2H, s, 
C=CH2, H-ll), 5.19 (IR, m, CHOH, H-I0), 2.16 (IH, m, OH), 1.38 (9H, s, OC(CH3)); 
8c(75.45MHz) 165.4, 147.2, 136.5, 133.6, 130.2, 129.5, 128.2, 128.0, 124.4, 73.7, 65 .2 
and 29.6; HRMS (EI) mlz 279.11 ~); C1JI17NOS requires 279.29. 
II (Yo "-0° 
o~
X ° OH OH 2-{Hydroxy- [2-hydroxy-4-( tetrahydro-pyran-2-
yloxy)-pbenyl]-methyl}-acrylic acid tert-butyl ester. 32 
Yield (0.09g, 57%); Rf 0.36 (3:7 EtOAC-Hexane); 8H (300MHz; CDCb) 7.45 (2H, m, 
Ar), 7.36 (1R, m, Ar), 6.67 (2R, m, C=CH, H-11), 5.10 (Ill, s, Ar-OH) , 4.96 (IR, d, 
J=12.3, CHOR, H-I0), 3.60 (2H, t, J=11.0, OCH2), 2.15 (IR, d, J=12.7, OH), l.98 (1R, 
m, CH2), l.88 (4R, m, 2CH2), 1.55 (9H, s, OC(CH3)3); oc(75.45MHz) 165.9, 160.2, 












V el " 
I 
F 2-[(2-Chloro-3,6-difluoro-phenyl)-hydroxy-methyl]-acrylic acid 
tert-butyl ester. 37 
Yield (0.039g, 46%); Rf 0.38 (3:7 EtOAC-Hexane); DH (300lVIHz; CDCb) 7.25 (2H, m, 
Ar), 6.15 (IH, m, C=CH2 , H-ll), 5.15 (lH, d, J=14.8, CHOR, R-I0), 2.08 (1R, d, 
J=14.6, OR), 1.54 (9R, s, OC(CH3)2); Dc(75.45lVIHz) 163.4, 160.1, 159.8, 148.2, 119.6, 
118.7, 118.5,63.4,29.6; LRMS (El) mlz 304 (M); ClJI15CIF20 3 requires 304.7. 
OH 0 oX 
F 
2-[(4-Fluoro-3-nitro-phenyl)-hydroxy-methyl]-acrylic acid 
tert-butyl ester. 33 
Yield (0.034g, 41%); IV 0.25 (3:7 EtOAC: Hexane); DH (300MHz; CDCh) 8.60 (1R, m, 
Ar), 7.45 (2H, m, Ar), 6.20 (2H, m, C=CH2, R-l1), 5.46 (1R, d, J=10.8, CHOR, H-I0), 
2.14 (lH, d, J=I1.0, OR), 1.45 (9H, s, OC(CH3)3); Dc(75.45MHz) 187.9, 156.3, 137.8, 













'CeXY1 Y / 0 ~ ~ I 0 ' ",-~ / I 
N CI 2-[(2-Chloro-6-methoxy-quinolin-3-yl)-hydroxy-
methyl]-acrylic acid tel1:-butyl ester. 40 
Yield (0 ,018g, 23 %); Rf 0.34 (3:7 EtOAC: Hexane); OH (300N1Hz; CDCb) 8.16 (IR, d, 
J=1.3, H-8), 7.87 (lH, ill, R-5), 7.25 (lR, m, R-3) 7.15 (d, J=1.2, R-7), 6.65 (2R, s, 
C=CH2, R-l1), 5.45 (IR, d, J=12 .1, CHOR, R-I0), 3.92 (3R, s, OCH3), 2.24 (lR, d, 
J=12.3, OH), 1.45 (9R, s, C(CH3)3); oc (75.45N1Hz) 165.6, 158.3, 143.0, 135.1, 134.8, 
132.5, 129.6, 129.5, 128.4, 127.0, 123.1, 122.7, 105.2, 66.5, 62.5, 55.6, 49.8 and 29.67; 
HRMS (FAB mlz 350 (M'"); C1sH2oCIN04 requires 349.81; Calc. for C, 6l.80; R, 5.76; 
CI, 10.13; N, 4.00; Found C, 60.94; H, 5.45, N, 4.01. 
O}l!l°H 
X 0 OH OMe 2-[Hydroxy-(4-hydroxy-2-methoxy-phenyl)-methyl]-acrylic 
acid tert-butylester. 29 
Yield (0. 120g, 63%); Rf 0.25 (3 :7 EtOAc: Hexane); OH (300MHz; CDCh) 7.70 (lR, ill, 
Ar), 6.45 (2R, m, Ar), 5.90 (2R, m, C=CH2 , H-ll), 5.19 (IH, d, J=12.6, CHOH, R-I0), 
3.84 (3H, s, OCB3), 2.23 (lR, d, J=12.8, OH), 1.44 (9H, s, C(CBJ)3); oc (75.45MHz) 













o OH 2-(Hydroxypbenyl-butyl)-acrylic acid tert-butyl ester. 31 
Yield (0.11g, 53%) as off-white crystals; Rf 0.37 (3 :7 EtOAc: Hexane); OH (200MHz; 
CDCb) 7.44 (5B, m, Ar), 6.01 (2H, S, C=CH2, H-11), 5.44 (1H, m, CHOH, H-10), 2.22 
(IH, m, OB), 1.48 (9H, s, C(CH3)3); oc (75.45:MHz) 163.2, 150.9, 140.2, 128.9, 128.8, 
128.7, 128.5, 122.4, 75.4, 72.1 and 29.0; LRMS (El) m/z 220.1; C1JIlS03 requires 
234.26. 
2-(Hydroxy-quinolin;..4-yl-methyl)-acrylic acid methyl ester. 20 
Yield (0.021g, 50%) as brown oil; Rf 0.33 (3:7 EtOAc: Hexane); oH(30011Hz, CDCb) 
8.78 (1H, d, J=2.4, H-1), 8.56 (lH, d, J=4.6, H-8), 7.95 (lH, d, J=4.8, B-5), 7.88 (lB, m, 
H-7), 7.78 (lHt, J=4.5, B-6), 7.56 (IH, d, J=2.0, H-2), 6.87 (2H, m., C=CH2, H-l1), 5.52 
(IH, d, J=13.2, CHOH, H-I0), 3.78 (3H, s, OCH3), 2.56 (1H, d, J=13.5, OB); 
oc(75.451tillz) 166.0, 155.4, 154.3, 154.0; 136.7, 132.4, 132.0, 129.0, 128.6, 125.4, 
123.2,82.6 and 54.0; LRMS (El) mlz 243 ; C1JI13N03, requires 243 .26. 
Me0}YQ 
o OH N02 2-[Hydroxy-(2-nitro-phenyl)-methyl]-acrylic acid methyl ester 
Rf 0.33 (3 :7 EtOAc: Hexane); oH(300MHz, CDCh) 8.42 (lB, d, J=4.5, Ar), 7.82 (2H, m, 











2.28 (1H, m, OlI), 3.78 (3H, s, OCH3); oc(75.45I'v1H.z) 164.7, 152.2, 150.3, 128.7, 128.3, 
128.1, 128.0, 122.1, 72 .5,51.2. 




, -...::::: X 
I ~ Method (a) for compound 50: A mixture of p-toluenesulfonamide 
(0.76 mmol), aldehyde (0.64 mmol) im methanol and acetic acid was stirred at 65°C for 
17hrs giving a sulfonamide product, which after purification was reacted with t-Butyl 
acrylate in the presence of DABCO. The reaction mixture was stirred at room 
temperature for 16hrs. Purification by column chromatography. 
Method (b) for compounds 42, 43, 44, 45, 46 and 47: A mixture of sulfonamide, acrylate/ 
acrylonitrile in 2-propanol was stirred at room temperature for 16hrs yielding a 
substituted sulfonamide derivative. The purification was done by column 
chromatography. 
U"P 
I? ' NH 
~ ~ I ?ok 
V / 
N CI 2- [(2-Chloro-6-methyl-q uinolin-3-yl)-( toluene-4-











Yield (0.755g, 66%) as off white oil; Rf 0.38 (3:7 EtOAc: Hexane); bH (300MHz; 
CDCb) 8.96 (lH, d, J=4.8, H-8), 8.17 (2H, m, H-3 and H-5), 7.80 (1H, d, J=4.4, R-7), 
7.32 (2H, t, J=4.4, Ar), 7.27 (2H, d, J=4.5, Ar), 6.4 (2H, S, C=CH2 , H-l1), 6.14 (IH, d, 
J=12.3, CHNH), 4.20 (lR, d, J=12.0, NHCH), 2.41 (6H, s, CH3), 1.44 (9H, s, C(Cll3)3); 
be (75MHz) 165.7, 152.2, 150.3, 147.2, 143.5, 136.8, 131.5, 130.0, 127.7, 127.5, 126.5, 
124.5, 124.2, 121.1, 77.1, 73.6, 62.4, 48.7, 29.6 and 21.6; HRMS (FAB) mlz 487 
C25H27C1N204S requires 487 .04; Calc. for C, 60.40; H, 5.65; Cl, 6.86; N, 5.42; S, 6.20; 
Found C, 59.27; H, 5.56, N, 6.95. 
'Os? 
qyCf'NH 0 oX I~ 
F 
N02 2-[(4-Fluoro-3-nitro-phenyl)-( toluene-4-sulfonylamino)-
methyl]-acrylic acid tert-butyl ester. 46 
Yield (0.78g, 72%) as brown oil; Rf 0.22 (3:7 EtOAc: Hexane) bH (400MHz; CDCb) 
8.01 (lR, d, J=4.0), 7.90 (2H, d, J=4.2), 7.80 (2H, d, J=4.4), 7.32 (2H, d, J=4 .1), 6.42 
(2H, s, C=CH2), 5.27 (lR, ill, NHCH), 2.43 (3H, s, CH3), 2.16 (lH, ill, NH), 1.60 (9H, s, 
C(CH3)3); be (7S.45MHz) 165.1, 152.2, 143.8, 141.6, 140.0, 131.5, l30.0, 129.9, 129.4, 
129.3, 127.8, 127.6, 126.6, 124.6, 121.1, 106.3, 72 .5, 48 .8, 29 .8 and 21.7; LRMS (F AB) 
mlz 450; C22H2SFN206S requires 450.13; Calc. for C, 54.99; H, 5.24; F, 3.95; N, 5.83; S, 













2-[Quinolin-4-yl-( toluene-4-sulfony lamin 0)-methyl]-
acrylic acid tert-butyl ester. 42 
Yield (0.09g, 68%) as brown oil; Rf 0.33 (3:7 EtOAc: Hexane); oH(3.00MHz, CDCb) 
8.98 (lR, d, J=8 .2, H-1), 8.02 (lH, d, J=4.0, H-8), 7.86 (2H, ffi, Ar), 7.56 (lR, d, J=4.0, 
H-5), 7.46 (lR, ffi, H-7), 7.40 (lH, t, J=4.2, H-6), 7.22 (lH, d, J=8.2, H-2), 6.98 (2R, ffi, 
Ar), 6.01 (2R, S, C=CH2 , H-ll), 5.6 (lll, d, J=10.4, NHCH), 2.48 (3H, s, CH3 ), 2.12 





'/ NH o 
:JrrCN ~ I I ~, N-[1-(5-Chloro-furan-2-yl)-2-cyano-a1lyl]-4-methyl-
benzenesulfonamide. 45 
Yield (0.24, 48%) as yellow oil; Rf 0,32 (3:7 EtOAc: Hexane); OH (400MHz; CDCh) 
7.82 (2ll, d, J=8.8, Ar), 7.32 (2H, d, J=8 .6, Ar), 6.2 (lR, s, C=CH2), 6.0 (2H, ffi, fur), 
4,82 (lR, ffi, NHCH), 2.42 (3H, S, Ar-CH3 ), 2.16 (3H, S, fur-CH3), 2.05 (lH, ffi, NH); 8c 

















Yield (0.23g, 63%) as white crystals; Rf 0.27 (3:7 EtOAc: Hexane); OH (400Jv1Hz; CDCh) 
7.80 (2H, m), 7.43 (2II, ill), 7.29 (IH, d, J=7.5), 7.09 (2H, d, J=7.2), 5.80 (2H, s, 
C=CH2), 4.59 (lH, m, NHCH), 2.43 (3H, s, CH3), 2.40 (lH, m, NH); Oc (75.45Jv1Hz) 




Yield (0.S29g, 53%) as white crystals; Rt 0.28 (3:7 EtOAc: Hexane); OH (400Jv1Hz; 
CDCh) 8.80 (IH, d, J=8.0, H-8), 8.78 (lH, ill, H-S), 8.41 (lH, d, J=8.2, H-7), 8.32 (lH, 
ill, H-3), 7.83 (2H, ill, Ar), 7.64 (2H, ill, Ar), 6.0 (2H, s, C=CH2), 4.80 (IH, d, J=13.S, 
NHCH), 2.43 (9H, s, CH3), 2.17 (IH, d, J=13.4, NH); oc (75.45 Jv1Hz) 156.7, 142.0, 
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